A practical reference on obesity research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-02. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
=== Contrast properties === Neutron scattering techniques particularly profit from availability of deuterated samples: The 1H and 2H cross sections are very distinct and different in sign, which allows contrast variation in such experiments. Further, a nuisance problem of normal hydrogen is its large incoherent neutron cross section, which is nil for 2H. The substitution of deuterium for normal hydrogen thus reduces scattering noise. Hydrogen is an important and major component in all materials of organic chemistry and life science, but it barely interacts with X-rays. As hydrogen atoms (including deuterium) interact strongly with neutrons; neutron scattering techniques, together with a modern deuteration facility, fills a niche in many studies of macromolecules in biology and many other areas.
== Further reading == Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. (May 2020). "Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction". N Engl J Med. 382 (20): 1883–1893. doi:10.1056/NEJMoa1915928. hdl:11370/94a25118-d24e-4efa-94a0-3b46279b519c. PMID 32222134.
Income inequality has traditionally been low in Denmark. According to OECD figures, in 2000 Denmark had the lowest Gini coefficient of all countries. However, inequality has increased during the last decades. According to data from Statistics Denmark, the Gini coefficient for disposable income has increased from 22.1 in 1987 to 29.3 in 2017. The Danish Economic Council found in an analysis from 2016 that the increasing inequality in Denmark is due to several components: Pre-tax labour income is more unequally distributed today than before, capital income, which is generally less equally distributed than labour income, has increased as share of total income, and economic policy is less redistributive today, both because public income transfers play a smaller role today and because the tax system has become less progressive. In international comparisons, Denmark has a relatively equal income distribution. According to the CIA World Factbook, Denmark had the twentieth-lowest Gini coefficient (29.0) of 158 countries in 2016. According to data from Eurostat, Denmark was the EU country with the seventh-lowest Gini coefficient in 2017. Slovakia, Slovenia, Czechia, Finland, Belgium and the Netherlands had a lower Gini coefficient for disposable income than Denmark.
The U.S. National Institute for Occupational Safety and Health derived a recommended exposure limit (REL) for silver nanomaterials (with <100 nm primary particle size) of 0.9 μg/m3 as an airborne respirable 8-hour time-weighted average (TWA) concentration. This is in comparison to its REL of 10 μg/m3 as an 8-hour TWA for total silver (including metal dust, fumes, and soluble compounds). It was found that the unbound silver cation is the ultimate toxicant, and ions formed extracellularly drive toxicity after exposure to Ag nanoparticles. Although silver nanoparticles are widely used in a variety of commercial products, there has only recently been a major effort to study their effects on human health. There have been several studies that describe the in vitro toxicity of silver nanoparticles to a variety of different organs, including the lung, liver, skin, brain, and reproductive organs. The mechanism of the toxicity of silver nanoparticles to human cells appears to be derived from oxidative stress and inflammation that is caused by the generation of reactive oxygen species (ROS) stimulated by either the Ag NPs, Ag ions, or both. For example, Park et al. showed that exposure of a mouse peritoneal macrophage cell line (RAW267.7) to silver nanoparticles decreased the cell viability in a concentration- and time-dependent manner. They further showed that the intracellular reduced glutathionine (GSH), which is a ROS scavenger, decreased to 81.4% of the control group of silver nanoparticles at 1.6 ppm.
Sources: en.wikipedia.org
Reaction with amines to form carbamates: ROC(O)Cl + H2NR' → ROC(O)-N(H)R' + HCl Reaction with alcohols to form carbonate esters: ROC(O)Cl + HOR' → ROC(O)-OR' + HCl Reaction with carboxylic acids to form mixed anhydrides: ROC(O)Cl + HO2CR' → ROC(O)−OC(O)R' + HCl Typically these reactions would be conducted in the presence of a base which serves to absorb the HCl. Alkyl chloroformate esters degrade to give the alkyl chloride, with retention of configuration:
== Mechanism of action == The iRGD peptide homes to and penetrates tumors through a 3-step process. First, the RGD sequence motif mediates binding to αVβ3 and αVβ5 integrins that are expressed on tumor endothelial cells. Second, upon αV binding, a protease cleavage event is activated, revealing the C-terminal CendR motif (R/KXXR/K) of the peptide. Third, the CendR motif is now able to bind to neuropilin-1, activating an endocytotic/exocytotic transport pathway. The pathway triggered by iRGD can be used for the enhanced transport of coupled and coadministered anti-cancer drugs into tumors.
heterokaryon A multinucleate cell containing nuclei with different genotypes, resulting from the fusion of two or more genetically distinct cells, either naturally (e.g. in certain types of sexual reproduction) or artificially (e.g. in genetic engineering).
Sources: en.wikipedia.org
It is specifically the beta subunit for each of these hormones that determines its specificity and function. Even further, the beta subunits of hCG, LH, FSH, and TSH show a high degree of sequence similarity in the first 114 amino acids of the polypeptide, with LH showing 85% similarity, FSH showing 36% similarity, and TSH showing 46% similarity. One likely reason for such high sequence similarity in hCG and LH is the fact that both respective beta subunits both bind to the same receptor, with their homology illustrating a common biological function and biochemical pathway.
== History == Composition is widely accepted to have been developed by Thomas Jackson in London around the late 18th century. His son, George Jackson, continued the business. His company, George Jackson, still trades today and supplies composition ornament made to the original methods and recipe.
Pizza Hut was launched on May 31, 1958, by two brothers, Dan and Frank Carney, both Wichita State students, as a single location in Wichita, Kansas. They were given a $600 loan from their mother to start the business. The brothers used the name Pizza Hut because the sign could only hold eight letters. Six months later they opened a second outlet, and within a year they were operating six locations. The brothers began franchising in 1959 with a location in Topeka, Kansas. By 1963, there were 24 locations. One early employee was future Pro Football Hall of Fame head coach Bill Parcells, who had worked for the company while a college student and football player at Wichita State University. Parcells was considering a franchise for a career (as well as law school), but instead chose to enter coaching, eventually becoming a head coach in the National Football League. By 1966, the company had 140 locations and had established its headquarters in Wichita. The first Pizza Hut restaurant east of the Mississippi River was opened in Athens, Ohio, in 1966 by Lawrence Berberick and Gary Meyers. The iconic Pizza Hut building style with the distinctive red roof was introduced in 1969, and was later incorporated into the corporate logo. By the end of the decade, there were over 300 locations. The Carneys took the company public in 1969. By 1971, Pizza Hut had more locations and higher sales than any of its competitors. In the early 1970s, Pizza Hut opened several other chains to diversify its menu.
Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective (e.g. by preventing receptor binding), to induce a specific cell signal (by activating receptors), to cause the immune system to attack specific cells, or to bring a drug to a specific cell type (such as with radioimmunotherapy which delivers cytotoxic radiation). Major applications include cancer, autoimmune diseases, asthma, organ transplants, blood clot prevention, and certain infections.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.